Physician profile
John P Kachoris
NPI 1073774147
$5,801.50
in general payments reported to CMS, 2019-2025
24 companies · $44.97 in 2025
The $44.97 reported for 2025 was less than what a typical Neurocritical Care provider received nationally (typical 2025 total: $95.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $3,063 · 2021: $1,028 · 2022: $381 · 2023: $578 · 2024: $258 · 2025: $44.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,750.00 | 2020-2021 | |
| Ceribell, INC. | $426.35 | 2023 | Ceribell Rapid Response Eeg |
| Ucb, INC. | $288.54 | 2019-2024 | Briviact |
| Medtronic, INC. | $152.10 | 2023 | Linq II |
| Genentech USA, INC. | $147.78 | 2021 | |
| Neurocrine Biosciences, INC. | $137.20 | 2022 | |
| Abbott Laboratories | $132.65 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $129.80 | 2021 | |
| Acorda Therapeutics, INC | $127.78 | 2019 | |
| Boston Scientific Corporation | $124.12 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $111.07 | 2022 | |
| Abbvie INC. | $44.97 | 2025 | |
| Genzyme Corporation | $31.54 | 2019 | |
| Assertio Therapeutics, INC. | $27.46 | 2019-2020 | |
| Csl Behring | $26.94 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $23.10 | 2019 | |
| Biogen, INC. | $18.70 | 2019 | |
| Eisai INC. | $17.47 | 2019 | |
| Ge Healthcare | $15.49 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.27 | 2019 | |
| Kyowa Kirin, INC. | $14.50 | 2020 | |
| Greenwich Biosciences, INC. | $14.17 | 2019 | |
| Grifols USA, LLC | $13.54 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kachoris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.